Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
Int J Clin Pharmacol Ther Toxicol
; 31(7): 358-60, 1993 Jul.
Article
em En
| MEDLINE
| ID: mdl-8370634
ABSTRACT
We studied 21 women with postmenopausal osteoporosis, treated with salmon calcitonin nasal spray (100 IU/daily) and calcium (1 g/daily) for six months. Bone mineral content (BMC), measured before and at the end of therapy with lumbar dual photon absorptiometry, showed a significant increase (p < 0.01). At the end of the study, there was also a clear improvement of osteoporotic pain. Among biochemical markers of bone turnover, there was a significant (p < 0.01) reduction of urinary excretion of hydroxyproline. No side effect was registered and all patients had a good compliance to therapy.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Calcitonina
/
Osteoporose Pós-Menopausa
Idioma:
En
Ano de publicação:
1993
Tipo de documento:
Article